Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced a second commercial agreement with Weill Cornell Medicine to expand the use of its Nociscan platform in a groundbreaking clinical trial. The trial, led by renowned neurosurgeon Roger Härtl, MD, will evaluate the long-term effects of lumbar microdiscectomy surgery with and without intradiscal bone marrow aspirate concentrate (BMAC) injection on patient outcomes and intervertebral disc health.
The study, titled “Bone Marrow Aspirate Concentrate Injection with MRI’s – a Prospective Randomized Controlled Trial” (IRB Protocol No. 24-09027977), aims to deepen understanding of degenerative disc disease (DDD) and its treatments. Nociscan, a SaaS platform that uses biomarkers and augmented intelligence to identify painful discs noninvasively, will be used to assess pain biomarkers and tissue composition over a two-year period.
“Our scientific interest focuses on clinical and basic science research surrounding innovative and less invasive surgical and biological treatment strategies for degenerative diseases of the spine,” said Dr. Härtl, founder and director of the Weill Cornell Medicine Center for Comprehensive Spine Care and co-director of Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center. “This trial strives to enhance our understanding of disc degeneration in patients, and illuminate chemical aspects of disc degeneration not available with traditional imaging.”
Ryan Bond, Chief Strategy Officer of Aclarion, emphasized the significance of the collaboration. “We are pleased to engage in this trial with Dr. Härtl and his team at Weill Cornell. Not only are Dr. Härtl and his colleagues renowned for their clinical excellence, their commitment to pioneering research is evident through this prospective randomized trial evaluating disc degeneration and the potential effects of bone marrow aspirate concentrate. Progressive trials such as this one are a clear example for how healthcare advances – investigating a major global health issue, like degenerative disc disease, while using innovative tools like Nociscan.”
Chronic low back pain (cLBP) affects approximately 266 million people worldwide, according to a study in Global Spine Journal (Ravindra VM, 2018). Aclarion’s Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs. It objectively quantifies chemical biomarkers associated with disc pain, and when used with other diagnostic tools, provides critical insights into the location of a patient’s low back pain, demonstrating a 97% surgical success rate when all Nociscan-identified pain positive discs are treated (Gornet M, Peacock J, et al. European Spine Journal. 2019;28:674-687).
This agreement marks the second trial at Weill Cornell Medicine to incorporate Nociscan, reinforcing Aclarion’s commitment to advancing spine care through innovative technology. For more information on Nociscan and Aclarion, visit www.aclarion.com and the company’s newsroom at https://tinyurl.com/aconnewsroom.
